Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With Hayfever
A Multicentre, Randomised, Double-blind, Placebo-controlled Parallel Group Clinical Trial to Investigate the Efficacy and Safety of Specific Sublingual Immunotherapy With SLITone Birch in Patients With Seasonal Birch Pollen Induced Rhinoconjunctivitis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, D-10117
- Charité Klinik für Dermatologie, Venerologie und Allergologie
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A history of birch pollen allergy
- Positive skin prick test to birch
- Positive conjunctival test to birch
- Positive specific Immunoglobulin E (IgE) to birch
Exclusion Criteria:
- Forced expiratory volume in 1 second (FEV1)<70% of predicted value
- History of seasonal allergy interfering with study
- History of symptomatic perennial allergy
- History of emergency visit or admission for asthma in the previous 12 month
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Sublingual immunotherapy
sublingual immunotherapy with drops applied once daily by single dose containers (200 STU per dose)
|
once daily intake of sublingual drops
Other Names:
|
|
PLACEBO_COMPARATOR: Placebo
placebo sublingual drops
|
once daily intake of sublingual drops
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Daily Rhinoconjunctivitis Symptom Score
Time Frame: Birch pollen season 2006
|
A total of 6 rhinoconjunctivitis symptoms are recorded (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes, watery eyes).
Each symptoms is scored on a scale from 0-3 (no symptoms-severe symptoms).
I.e. the total daily score can be 0-18.
|
Birch pollen season 2006
|
|
Daily Rhinoconjunctivitis Rescue Medication Score
Time Frame: Birch pollen season 2006
|
Rescue medication (desloratadine tablets, budesonide nasal spray, prednisone tablets) used for treatment of rhinoconjunctivitis symptoms not controlled by the study medication, were recorded.
The total daily score was 0-30 (No medication-Maximum use of medication).
|
Birch pollen season 2006
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Global Improvement of Rhinoconjunctivitis Symptoms Assessed by the Subjects
Time Frame: Birch pollen season 2006
|
The number of participants who reported improved overall symptoms compared to the previous birch pollen season (each patient was asked to compare his/her symptoms in the 2006 birch pollen season with the symptoms in the 2005 birch pollen season).
|
Birch pollen season 2006
|
|
Adverse Events
Time Frame: Birch pollen season 2006
|
An adverse event was defined as: Any untoward medical occurence in a patient or clinical trial subject administered a trial product and which does not necessarily have a causal relationship with this treatment (International Conference of Harmonisation (ICH) Harmonised Tripartite Guideline E2A, Step 5).
|
Birch pollen season 2006
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Margitta Worm, MD, Prof., Charite University, Berlin, Germany
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- SHX0712
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.